First-Line Treatment of Advanced Biliary Tract Cancers (BTCs)

First-Line Treatment of Advanced Biliary Tract Cancers (BTCs)

Use of first-line (1L) IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin (gem-cis) chemotherapy in patients with locally advanced or metastatic biliary tract cancers

This Ask the Expert special issue offers information on the use of durvalumab for the first-line treatment of advanced biliary tract cancers. It features expert insights on efficacy results from the TOPAZ-1 clinical trial, the prevalence of genomic alterations and associated outcomes in the biomarker-evaluable patient population, and strategies for community healthcare providers who are looking to incorporate this treatment into their practice.

Download
First-Line Treatment of Advanced BTCs

First-Line Treatment of Advanced Biliary Tract Cancers (BTCs)

Use of first-line (1L) IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin (gem-cis) chemotherapy in patients with locally advanced or metastatic biliary tract cancers

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.

We Value Your Feedback! Tell Us How You Consume Content